Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400  mg

ConclusionThe two-compartment transit model adequately describes the absorption and distribution of imatinib in healthy volunteers. For patients, a lower clearance of imatinib compared to healthy volunteer was estimated by the model. The model can be applied for dose individualization based on trough concentrations assuming no significant differences in absorption between patients and healthy volunteers.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research